Abstract

BackgroundJIA is the common chronic rheumatic disease in children that may continue to be active in adulthood. The new laboratory markers are needed to adjust therapy of JIA to the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Soluble IL-2R, IFN-γ and Neopterin as Immunologic Markers in Patients with Tuberculosis
Yon Ju Ryu ... Su Hyun Kim
Tuberculosis and Respiratory Diseases | VOL. 53
Yon Ju Ryu, et. al.Yon Ju Ryu ... Su Hyun Kim
01 Jan 2002
Elevated Soluble CD8 Antigen and Soluble Interleukin-2 Receptors in the Sera of Patients with Juvenile Rheumatoid Arthritis
Peter P Sfikakis ... Robert N Lipnick
Clinical Immunology and Immunopathology | VOL. 68
Peter P Sfikakis, et. al.Peter P Sfikakis ... Robert N Lipnick
01 Jul 1993
Serum Level of a Soluble Receptor for Interleukin-2 as a Prognostic Factor in Patients with Gastric Cancer
Michio Maeta ... Masahide Ikeguchi
Oncology | VOL. 56
Michio Maeta, et. al.Michio Maeta ... Masahide Ikeguchi
01 Apr 1999
Serum levels of β2-microglobulin, neopterin, TNF-α and soluble receptors of TNF-α and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection
Xavier Filella ... José Luis Bedini
Clinical Microbiology and Infection | VOL. 4
Xavier Filella, et. al.Xavier Filella ... José Luis Bedini
01 Jan 1998
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers